Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
21 May, 2019 16:43 IST
Lupin receives USFDA approval for Tadalafil tablets USP
Source: IRIS | 07 Feb, 2019, 12.12PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received approval for its Tadalafil Tablets USP, 20 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s Adcirca Tablets, 20 mg.

Lupin’s Tadalafil Tablets USP, 20 mg is the generic version of Eli Lilly and Company’s Adcirca Tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Tadalafil Tablets, 20 mg (RLD: Adcirca) had annual sales of approximately USD 474.3 million in the US (IQVIA MAT December 2018).

Shares of the company declined Rs 22.35, or 2.65%, to trade at Rs 819.60. The total volume of shares traded was 143,872 at the BSE (11.14 a.m., Thursday).

Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer